跳至主要内容
临床试验/NCT03658811
NCT03658811已完成不适用

Evaluation of the Safety and Efficacy of Intense Pulse Light Treatment With Meibomian Gland Expression of Upper Eyelids for Dry Eye Disease

Toyos Clinic2 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2018年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Toyos Clinic
入组人数
19
试验地点
2
主要终点
Non-invasive Tear Break up Time (TBUT)

研究概览

简要总结

Upper eyelid treatment has not been used with previously described methods of treatment of dry eye disease using intense pulsed light therapy because the upper lids disease was typically not as advanced as lower lid and because direct treatment of the upper lid was not felt to be necessary as each light pulse extended over the entire periorbita even when concentrated on the lower lid.

详细描述

Dry eye disease is an under-diagnosed and growing problem. Intense pulsed light has been a proven method of improving the signs and symptoms of meibomian gland dysfunction including lid margin vascularity, meibum viscosity, OSDI mean score and tear break up. This study looks at the safety and effect of treatment of upper lids only to evaluate the safety and efficacy of direct upper lid treatment on the signs and symptoms of dry eye.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • subjects older than 18
  • cloudy or inspissated meibomian glands in both upper lids
  • ocular pain due to dry eye unrelieved by current or prior use of conservative topical dry eye medications including but not limited to over the counter artificial tears, lifitegrast, cyclosporine, or sodium chloride.

排除标准

  • Patients with eyelid abnormalities
  • intense pulsed light treatment within the past year.
  • Patients on oral retinoids,
  • patients undergoing intraocular surgery within the past year,
  • patients with uncontrolled ocular disease,
  • Fitzpatrick skin type V or VI,
  • neuro-paralysis in the planned treatment area in the past 6 months,
  • pre-cancerous lesions in the planned treatment area.
  • New topical eye treatments,
  • previous expression of meibomian glands,
  • legally blind in one eye.

研究组 & 干预措施

Upper eyelid meibomian gland dysfunction

Experimental

Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments

干预措施: intense pulsed light (Device)

结局指标

主要结局

Non-invasive Tear Break up Time (TBUT)

时间窗: 2 weeks

average of 3 measurements (in seconds) using fluorescein dye and stopwatch to monitor first sign of tear film break up

次要结局

  • Measure of Visual Analog Scale Pain(2 weeks)
  • Measure of Visual Analog Scale Pain Over Last 24 Hours(24 hours)
  • Ocular Discomfort Frequency Assessment on Visual Analog Scale(24 hours)

研究者

发起方
Toyos Clinic
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验